# Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)

> **NCT00464919** · PHASE2 · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** tegafur/uracil (UFUR®)

## Key facts

- **NCT ID:** NCT00464919
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** —
- **Final completion:** 2009-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2009-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00464919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00464919, "Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00464919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*